Medicine and Dentistry
Age
7%
Anti-Inflammatory Drug
8%
Biosimilar
6%
Carbohydrate Intake
6%
Case-Control Study
6%
Cataract
6%
Cohort Analysis
14%
Cohort Effect
13%
Colectomy
14%
Combination Therapy
8%
Crohn's Disease
8%
Cystatin C
6%
Cytokine
8%
Disease
13%
Drug
12%
Experience
6%
Follow up
13%
Frailty
6%
Granulocyte
6%
Hazard Ratio
14%
Health Care Cost
6%
Hospital
5%
Infection
6%
Inflammatory Bowel Disease
23%
Linoleic Acid
6%
Macrophage
7%
Medical Record
5%
Older Adult
6%
Patient
100%
Patient with Crohn's Disease
17%
Patient with Inflammatory Bowel Disease
24%
Patient with Ulcerative Colitis
10%
Person
5%
Polyunsaturated Fatty Acid
6%
Pooled Analysis
6%
Portal Vein Thrombosis
6%
Primary Sclerosing Cholangitis
6%
Prospective Cohort Study
13%
Proteinase Inhibitor
6%
Quality of Life
11%
Randomized Controlled Trial
6%
Spontaneous Remission
21%
Surgery
10%
T-Helper Cell
6%
Therapeutic Procedure
48%
TNF Inhibitor
13%
Ulcerative Colitis
8%
Pharmacology, Toxicology and Pharmaceutical Science
Adalimumab
7%
Anti-Inflammatory Drug
15%
Antiinflammatory Activity
12%
Atorvastatin
18%
Biological Product
6%
Calgranulin
5%
Cataract
6%
Cohort Study
28%
Crohn's Disease
37%
Endotoxin
6%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
7%
Immunosuppressive Agent
6%
Incidence
6%
Infection
13%
Inflammation
18%
Inflammatory Bowel Disease
37%
Observational Study
6%
Oxidized Low Density Lipoprotein
6%
Remission
26%
Steroids
7%
Tumor Necrosis Factor
15%
Tumor Necrosis Factor Inhibitor
13%
Ulcerative Colitis
13%
Vein Thrombosis
6%
Immunology and Microbiology
Alpha 1-Antitrypsin
6%
Blood Plasma
6%
CD16
14%
Crohn's Disease
7%
Death Receptor
6%
Density
6%
Golimumab
6%
Immunosuppressive Drug
6%
Inflammation
15%
Inflammatory Bowel Disease
16%
Inflammatory Disorder
6%
Macrophage
21%
Monocyte
64%
Mucosa
6%
Pulmonary Inflammation
6%
Tumor Necrosis Factor
15%
Ulcerative Colitis
7%
